Pravastatin modulates macrophage functions of Leishmania (L.) amazonensis-infected BALB/c mice

Experimental Parasitology

Volumn 134, Issue 1, 2013, Pages 18-25

  Kückelhaus, Carlos S ^a   Kückelhaus, Selma A S ^a   Tosta, Carlos Eduardo ^a   Muniz Junqueira, Maria Imaculada ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Hydrogen peroxide; Leishmania (L.) amazonensis; Nitric oxide; Phagocytosis; Pravastatin; TNF; Tumor necrosis factor

Indexed keywords

HYDROGEN PEROXIDE; IMMUNOGLOBULIN RECEPTOR; NITRIC OXIDE; PATTERN RECOGNITION RECEPTOR; PRAVASTATIN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CELL PHAGOCYTOSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; FEMALE; IMMUNOMODULATION; LEISHMANIASIS; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; YEAST CELL;

ANIMALS; FEMALE; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MICE; MICE, INBRED BALB C; NITRIC OXIDE; PHAGOCYTOSIS; PRAVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875114576     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2013.01.020     Document Type: Article

References (54)

1. Ando H., Takamura T., Kobayashi K.I. Does pravastatin affect circulating levels of soluble TNF receptor 2 in hypercholesterolemic patients?. Atherosclerosis 2003, 166:413-414.
2. Ando H., Takamura T., Ota T., Nagai Y., Kobayashi K.I. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. The Journal of Pharmacology and Experimental Therapeutics 2000, 294:1043-1046.
3. Benati D., Ferro M., Savino M.T., Ulivieri C., Schiavo E., Nuccitelli A., Pasini F.L., Baldari C.T. Opposite effects of simvastatin on the bactericidal and inflammatory response of macrophages to opsonized S. aureus. Journal of Leukocyte Biology 2010, 87:433-442.
4. Bern C., Maguire J.H., Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Neglected Tropical Diseases 2008, 2:e313.
5. Blackwell J.M., Ezekowitz R.A., Roberts M.B., Channon J.Y., Sim R.B., Gordon S. Macrophage complement and lectin-like receptors bind Leishmania in the absence of serum. The Journal of Experimental Medicine 1985, 162:324-331.
6. Bogdan C., Röllinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. International Journal for Parasitology 1998, 28:121-134.
7. Bokoch G.M. Regulation of innate immunity by Rho GTPases. Trends in Cell Biology 2005, 15:163-171.
8. Bosetto M.C., Giorgio S. Leishmania amazonensis: Multiple receptor-ligand interactions are involved in amastigote infection of human dendritic cells. Experimental Parasitology 2007, 116:306-310.
9. Brown G.D. Innate antifungal immunity: the key role of phagocytes. Annual Reviews of Immunology 2011, 29:1-21.
10. Chakraborty P., Ghosh D., Basu M.K. Modulation of macrophage mannose receptor affects the uptake of virulent and avirulent Leishmania donovani promastigotes. The Journal of Parasitology 2001, 87:1023-1027.
11. Chow S.C. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Archivum Immunologiae et Therapiae Experimentalis 2009, 57:243-251.
12. Da-Cruz A.M., Oliveira M.P., De Luca P.M., Mendonça S.C.F., Coutinho S.G. Tumor necrosis factor-α in human American tegumentary leishmaniasis. Memórias do Instituto Oswaldo Cruz 1996, 91:225-229.
13. Dominguez P.M., López-Bravo M., Kalinke U., Ardavín C. Statins inhibit iNOS-mediated microbicidal potential of activated monocyte-derived dendritic cells by an IFN-β-dependent mechanism. European Journal of Immunology 2011, 41:3330-3339.
14. Franzoni F., Quinõnes-Galvan A., Regoli F., Ferranninni E., Galetta F. A comparative study of the in vitro antioxidant activity of statins. International Journal of Cardiology 2003, 90:317-321.
15. Garg R., Dube A. Animal models for vaccine studies for visceral leishmaniasis. The Indian Journal Medical Research 2006, 123:439-454.
16. Giudice A., Camada I., Leopoldo P.T.G., Pereira J.M.B., Riley L.W., Wilson M.E., Ho J.L., Jesus A.R., Carvalho E.M., Almeida R.P. Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in tegumentary leishmaniasis. BMC Infectious Diseases 2007, 7:7.
17. Gomes I.N., Palma L.C., Campos G.O., Lima J.G.B., Almeida T.F., Menezes J.P.B., Ferreira C.A.G., Santos R.R., Buck G.A., Manque P.A.M., Ozaki L.S., Probst C.M., Freitas L.A.R., Krieger M.A., Veras P.S.T. The scavenger receptor MARCO is involved in Leishmania major infection by CBA/J macrophages. Parasite Immunology 2009, 31:188-198.
18. Green L.C., Wagner D.A., Glogwiski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite and nitrate in biological fluids. Analytical Biochesmitry 1982, 126:131-138.
19. Grip O., Janciauskiene S., Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. European Journal of Pharmacology 2000, 410:83-92.
20. Hespanhol R.C., Soeiro M.N.C., Meuser M.B., Meirelles M.N.S.L., Côrte-Real S. The expression of mannose receptors in skin fibroblast and their involvement in Leishmania (L.) amazonensis invasion. Journal of Histochemistry and Cytochemistry 2005, 53:35-44.
21. Hoffman M., Weinberg J.B. Tumor necrosis factor-alpha induces increased hydrogen peroxide production and Fc receptor expression, but not increased Ia antigen expression by peritoneal macrophages. Journal of Leukocyte Biology 1987, 42:704-707.
22. Kim Y.C., Kim K.K., Shevach E.M. Simvastatin induces Foxp3 + T regulatory cells by modulation of transforming growth factor-β signal transduction. Immunology 2010, 130:484-493.
23. Kocyigit A., Keles H., Selek S., Guzel S., Celik H., Erel O. Increased DNA damage and oxidative stress in patients with cutaneous leishmaniasis. Mutation Research 2005, 585:71-78.
24. Kückelhaus C.S., Kückelhaus S.A., Muniz-Junqueira M.I. Influence of long-term treatment with pravastatin on the survival, evolution of cutaneous lesion and weight of animals infected by Leishmania amazonensis. Experimental Parasitology 2011, 127:658-664.
25. Lee K.J., Moon J.Y., Choi H.K., Kim H.O., Hur G.Y., Jung K.H., Lee S.Y., Kim J.H., Shin C., Shim J.J., In K.H., Yoo S.H., Kang K.H., Lee S.Y. Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. Clinical and Experimental Immunology 2010, 161:298-305.
26. Liew F.Y., Millot S., Parkinson C., Palmer R.M., Moncada S. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. Journal of Immunology 1990, 144:4794-4797.
27. Liew F.Y., Parlinson C., Millot S., Severn A., Carrier M. Tumour necrosis factor (TNFα) in leishmaniasis. I. TNFα mediates host protection against cutaneous leishmaniasis. Immunology 1990, 69:570-573.
28. Maltezou H.C. Drug resistance in visceral leishmaniasis. Journal of Biomedicine and Biotechnology 2010, ID 617521.
29. Matic M., Simon S.R. Tumor necrosis factor release from lypopolysaccharide-stimulated human monocytes: lypopolysaccharide tolerance in vitro. Cytokine 1991, 3:576-583.
30. Mishra B.B., Singh R.K., Srivastava A., Tripathi V.J., Tiwari V.K. Fighting against Leishmaniasis: search of alkaloids as future true potential anti-leishmanial agents. Mini Reviews in Medicinal Chemistry 2009, 9:107-123.
31. Mosser D.M. The many faces of macrophage activation. Journal of Leukocyte Biology 2003, 73:209-212.
32. Mosser D.M., Edelson P.J. The mouse macrophage receptor for C3bi (CR3) is a major mechanism in the phagocytosis of Leishmania promastigotes. The Journal of Immunology 1985, 135:2785-2789.
33. Mukbel R.M., Patten C., Gibson K., Ghosh M., Petersen C., Jones D.E. Macrophage killing of Leishmania amazonensis amastigotes requires both nitric oxide and superoxide. The American Journal of Tropical Medicine and Hygiene 2007, 76:669-675.
34. Muniz-Junqueira M.I., Karnib S.R., Paula-Coelho V.N., Junqueira-Jr L.F. Effects of pravastatin on the in vitro phagocytic function and hydrogen peroxide production by monocytes of healthy individuals. International Immunopharmacology 2006, 6:53-60.
35. Muniz-Junqueira M.I., Peçanha L.M.F., Silva-Filho V.L., Cardoso M.C.A., Tosta C.E. Novel microtechnique for assessment of postnatal maturation of the phagocytic function of neutrophils and monocytes. Clinical Diagnostic Laboratory Immunology 2003, 10:1096-1102.
36. Muniz-Junqueira M.I., Silva F.O., Paula-Jr M.R., Tosta C.E. Thalidomide influences the function of macrophages and increases the survival of Plasmodium berghei-infected CBA mice. Acta Tropica 2005, 94:128-138.
37. Murray H.W. Susceptibility of Leishmania to oxygen intermediates and killing by normal macrophages. Journal of Experimental Medicine 1981, 153:1302-1315.
38. Niessner A., Steiner S., Speidl W.S., Pleiner J., Seidinger D., Maurer G., Goronzy J.J., Weyand C.M., Kopp C.W., Huber K., et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006, 189:408-413.
39. Nylén S., Akuffo H. Tracing immunity to human leishmaniasis. Future Microbiology 2009, 4:241-254.
40. Ozbilge H., Aksoy N., Kilic E., Saraymen R., Yazar S., Vural H. Evaluation of oxidative stress in cutaneous leishmaniasis. The Journal of Dermatology 2005, 32:7-11.
41. Pahan K., Sheikh F.G., Namboodiri A.M., Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. The Journal of Clinical Investigation 1997, 100:2671-2679.
42. Pick E., Keisari Y. A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. Journal of Immunological Methods 1980, 38:161-170.
43. Reithinger R. Leishmaniases' burden of disease: Ways forward for getting from speculation to reality. PLoS Neglected Tropical Diseases 2008, 2:e285.
44. Ritter U., Mattner J., Rocha J.S., Bogdan C., Körner H. The control of Leishmania (Leishmania) major by TNF in vivo is dependent on the parasite strain. Microbes and Infection 2004, 6:559-565.
45. Rosenson R.S., Tangney C.C., Casey L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999, 353:983-984.
46. Sampaio R.N.R., Marsden P.D. Tratamento da forma mucosa de leishmaniose sem resposta a glucantime, com anfotericina b lipossomal. Revista da Sociedade Brasileira de Medicina Tropical 1997, 30:125-128.
47. Sharma U., Singh S. Immunobiology of leishmaniasis. Indian Journal of Experimental Biology 2009, 47:412-423.
48. Shovman O., Levy Y., Gilburd B., Shoenfeld Y. Antiinflammatory and immunomodulatory properties of statins. Immunologic Research 2002, 25:271-285.
49. Solheim S., Seljeflot I., Arnesen H., Eritsland J., Eikvar L. Reduced levels of TNFα in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atherosclerosis 2001, 157:411-415.
50. Wilson M.E., Pearson R.D. Evidence that Leishmania donovani utilizes a mannose receptor on human mononuclear phagocytes to establish intracellular parasitism. The Journal of Immunology 1986, 136:4681-4688.
51. Witte M.B., Barbul A. Role of nitric oxide in wound repair. The American Journal of Surgery 2002, 183:406-412.
52. Woelbing F., Kostka S.L., Moelle K., Belkaid Y., Sunderkoetter C., Verbeek S., Waisman A., Nigg A.P., Knop J., Udey M.C., von Stebut E. Uptake of Leishmania major by dendritic cells is mediated by Fcγ receptors and facilitates acquisition of protective immunity. Journal of Experimental Medicine 2006, 203:177-188.
53. World Health Organization, 2011. Leishmaniasis disease burden. (available at: ). http://www.who.int/leishmaniasis/burden/en/.
54. Yamey G., Torreele E. The world's most neglected diseases. British Medical Journal 2002, 325:176-177.